Skip to main content
Erschienen in: Journal of Gastroenterology 7/2009

01.07.2009 | Original Article—Alimentary Tract

Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring

verfasst von: Katsuhiko Iwakiri, Noriyuki Kawami, Hirohito Sano, Yuriko Tanaka, Mariko Umezawa, Makoto Kotoyori, Yoshio Hoshihara, Choitsu Sakamoto

Erschienen in: Journal of Gastroenterology | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Combined multi-channel intra-luminal impedance and pH (Mll-pH) monitoring can detect gastro-esophageal reflux and identify acid and non-acid reflux (NAR) events. It can be used for patients with persistent symptoms who are having proton pump inhibitor (PPI) therapy. The aim of this study is to determine the frequency of acid reflux and NAR and to establish their relationship with persistent reflux symptoms in Japanese patients with non-erosive reflux disease (NERD) who are on a double-dose of PPI therapy.

Methods

Thirteen patients with NERD, with persistent reflux symptoms, despite taking PPI at least twice daily, were included in this study. Twenty-four-hour combined Mll-pH monitoring was carried out on all patients and reflux episodes were detected by impedance channels, located at 3, 5, 7, 9, 15 and 17 cm above the lower esophageal sphincter (LES) and classified into acid reflux and NAR, based on pH data from 5 cm above the LES. A positive symptom index (SI) was declared, if at least half of the symptoms were preceded by reflux episodes within 5 min.

Results

A total of 916 liquid reflux episodes were detected, and a total of 171 symptoms were recorded. Eight (4.7%) of 171 symptoms were related to acid reflux, and 68 (39.8%) were related to NAR. Seven (53.8%) patients had a positive SI and in these seven patients, a total of 79 symptoms were recorded. 5 (6.3%) of the 79 symptoms were related to acid reflux and 44 (55.7%) were related to NAR.

Conclusions

Persistent reflux symptoms, in SI-positive patients with NERD on double-dose PPI therapy, are more likely to be associated with primarily non-acid reflux.
Literatur
1.
Zurück zum Zitat Richter JE, Bockenek W. Oral pantprazole for erosive esophagitis: a placebo-controlled randomized clinical trial. Pantoprazole US GERD study group. Am J Gastroenterol. 2000;95:3071–80.PubMedCrossRef Richter JE, Bockenek W. Oral pantprazole for erosive esophagitis: a placebo-controlled randomized clinical trial. Pantoprazole US GERD study group. Am J Gastroenterol. 2000;95:3071–80.PubMedCrossRef
2.
Zurück zum Zitat Bardhan KD, Hawkey CJ, Long RG, Morgan AG, Wormsley KG, Moules IK, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther. 1995;9:145–51.PubMedCrossRef Bardhan KD, Hawkey CJ, Long RG, Morgan AG, Wormsley KG, Moules IK, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther. 1995;9:145–51.PubMedCrossRef
3.
Zurück zum Zitat Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996;91:1749–57.PubMed Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996;91:1749–57.PubMed
4.
Zurück zum Zitat Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther. 2001;15:227–31.PubMedCrossRef Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther. 2001;15:227–31.PubMedCrossRef
5.
Zurück zum Zitat Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–64.PubMedCrossRef Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–64.PubMedCrossRef
6.
Zurück zum Zitat Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next? Aliment Pharmacol Ther. 2005;22:79–94.PubMedCrossRef Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next? Aliment Pharmacol Ther. 2005;22:79–94.PubMedCrossRef
7.
Zurück zum Zitat Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol. 2008;6:393–400.PubMedCrossRef Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol. 2008;6:393–400.PubMedCrossRef
8.
Zurück zum Zitat Tutuian R, Vela MF, Shay SS, Castell DO. Multichannel intraluminal impedance in esophageal function testing and gastroesophageal reflux monitoring. J Clin Gastroenterol. 2003;37:206–15.PubMedCrossRef Tutuian R, Vela MF, Shay SS, Castell DO. Multichannel intraluminal impedance in esophageal function testing and gastroesophageal reflux monitoring. J Clin Gastroenterol. 2003;37:206–15.PubMedCrossRef
9.
Zurück zum Zitat Shay S, Tutuian R, Sifrim D, Vela M, Wise J, Balaji N, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004;99:1037–43.PubMedCrossRef Shay S, Tutuian R, Sifrim D, Vela M, Wise J, Balaji N, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004;99:1037–43.PubMedCrossRef
10.
Zurück zum Zitat Sifrim D, Castell D, Dent J, Kahrilus PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53:1024–31.PubMedCrossRef Sifrim D, Castell D, Dent J, Kahrilus PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53:1024–31.PubMedCrossRef
11.
Zurück zum Zitat Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the in the distal esophagus. Am J Gastroenterol. 1974;62:323–32. Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the in the distal esophagus. Am J Gastroenterol. 1974;62:323–32.
12.
Zurück zum Zitat Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–402.PubMedCrossRef Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–402.PubMedCrossRef
13.
Zurück zum Zitat Balaban DH, Yamamoto Y, Liu J, Pehlivanov N, Wisniewski R, DeSilvey D, et al. Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. Gastroenterology. 1999;116:29–37.PubMedCrossRef Balaban DH, Yamamoto Y, Liu J, Pehlivanov N, Wisniewski R, DeSilvey D, et al. Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. Gastroenterology. 1999;116:29–37.PubMedCrossRef
14.
Zurück zum Zitat Kinoshita Y, Kobayashi T, Kato M, Asahina K, Haruma K, Shimatani T, et al. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol. 2006;41:554–61.PubMedCrossRef Kinoshita Y, Kobayashi T, Kato M, Asahina K, Haruma K, Shimatani T, et al. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol. 2006;41:554–61.PubMedCrossRef
15.
Zurück zum Zitat Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: A crossover comparative study in homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther. 2006;79:144–52.PubMedCrossRef Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: A crossover comparative study in homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther. 2006;79:144–52.PubMedCrossRef
Metadaten
Titel
Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring
verfasst von
Katsuhiko Iwakiri
Noriyuki Kawami
Hirohito Sano
Yuriko Tanaka
Mariko Umezawa
Makoto Kotoyori
Yoshio Hoshihara
Choitsu Sakamoto
Publikationsdatum
01.07.2009
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 7/2009
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0070-6

Weitere Artikel der Ausgabe 7/2009

Journal of Gastroenterology 7/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.